Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Hypertension | Research

Developing a research database of primary aldosteronism: rationale and baseline characteristics

Authors: Wen Wang, Yuanmei Li, Qianrui Li, Tingting Zhang, Wei Wang, Dan Mo, Haoming Tian, Tao Chen, Yan Ren

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Management of primary aldosteronism (PA) has become a research hotspot in the field of endocrinology. To obtain reliable research evidence, it is necessary to establish a high-quality PA research database.

Methods

The establishment of PA research database involved two steps. Firstly, patients with confirmation of PA diagnosis between 1 Jan 2009 to 31 Aug 2019 at West China Hospital were identified and data were extracted. Secondly, patients with confirmatory testing for PA will be enrolled into a prospective cohort. Data will be prospectively collected based on the case report forms since 1 Sep 2019. We evaluated the quality of research database through assessment of quality of key variables.

Results

Totally, 862 patients diagnosed as PA were identified, of which 507 patients who had positive confirmatory testing for PA were included into the retrospective database. Among 862 patients diagnosed as PA, the mean systolic blood pressure (SBP) was 156.1 (21.7) mmHg, mean diastolic blood pressure (DBP) was 97.2 (14.5) mmHg. Among included patients, the mean serum potassium level was 2.85 (IQR, (2.47–3.36) mmol/L, and the mean plasma aldosterone concentration (PAC) was 28.1 (IQR, 20.0–40.4) ng/dL. The characteristics of patients with positive confirmatory testing for PA were similar. Validation of data extracting and linking showed the accuracy were 100%. Evaluation of missing data showed that the completeness of BMI (95.9%), SBP (99.4%) and DBP (99.4%) were high.

Conclusion

Through integrating retrospective and prospective cohort of PA, a research database of PA with high quality and comprehensive data can be established. We anticipate that the research database will provide a high level of feasibility for management of PA in China.
Literature
9.
go back to reference Wang L, Li N. Detection of secondary causes and coexisting diseases in hypertensive patients: OSA and PA are the common causes associated with hypertension. BioMed Res Int. 2017;2017:8295010.PubMedPubMedCentral Wang L, Li N. Detection of secondary causes and coexisting diseases in hypertensive patients: OSA and PA are the common causes associated with hypertension. BioMed Res Int. 2017;2017:8295010.PubMedPubMedCentral
14.
go back to reference Berends AMA, Buitenwerf E, Gruppen EG, Sluiter WJ, Bakker SJL, Connelly MA, et al. Primary aldosteronism is associated with decreased low-density and high-density lipoprotein particle concentrations and increased GlycA, a pro-inflammatory glycoprotein biomarker. Clin Endocrinol. 2019;90(1):79–87. https://doi.org/10.1111/cen.13891.CrossRef Berends AMA, Buitenwerf E, Gruppen EG, Sluiter WJ, Bakker SJL, Connelly MA, et al. Primary aldosteronism is associated with decreased low-density and high-density lipoprotein particle concentrations and increased GlycA, a pro-inflammatory glycoprotein biomarker. Clin Endocrinol. 2019;90(1):79–87. https://​doi.​org/​10.​1111/​cen.​13891.CrossRef
19.
go back to reference Li YM, Wang W, Li QR, Chen T, Mo D, Zhang TT, et al. Diagnostic efficiency of different screening indexes for primary Aldosteronism. J Sichuan Univ. 2020;51(3):278–86. Li YM, Wang W, Li QR, Chen T, Mo D, Zhang TT, et al. Diagnostic efficiency of different screening indexes for primary Aldosteronism. J Sichuan Univ. 2020;51(3):278–86.
24.
Metadata
Title
Developing a research database of primary aldosteronism: rationale and baseline characteristics
Authors
Wen Wang
Yuanmei Li
Qianrui Li
Tingting Zhang
Wei Wang
Dan Mo
Haoming Tian
Tao Chen
Yan Ren
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00794-7

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.